Literature DB >> 12038699

Consequences of late referral in diabetic renal disease.

E Ritz1.   

Abstract

The incidence of patients with end-stage renal disease and type 2 diabetes has increased tremendously over the past few decades. Unfortunately, many patients with diabetes are referred late to nephrologists. Currently, between a quarter and a third of European patients are referred to a nephrologist less than one month prior to the initiation of renal replacement therapy. The causes of late referral can be categorised into physician-related factors, patient-related factors, and factors related to the disease itself, such as the lack of a good general indicator of renal function. The consequences of late referral include poorer status upon referral, higher rates of hospitalisation and higher costs, and even increased mortality. Several interventions can be undertaken to improve the referral of patients with renal disease and diabetes, including improved medical education, better communication between GPs and nephrologists, adoption of a team approach between nephrologists, diabetologists and GPs, improved patient information, development of guidelines, and financial incentives to encourage earlier referral of these patients.

Entities:  

Mesh:

Year:  2002        PMID: 12038699     DOI: 10.1007/s005920200002

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  2 in total

1.  Characteristics of end stage renal disease diabetic patients in two countries with different socioeconomic conditions.

Authors:  Emmanuel I Agaba; Oladipo Adeniyi; Karen S Servilla; Dorothy J Vanderjagt; Robert H Glew; Antonios H Tzamaloukas
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

2.  Factors influencing general practitioner referral of patients developing end-stage renal failure: a standardised case-analysis study.

Authors:  Anthony J Montgomery; Hannah M McGee; William Shannon; John Donohoe
Journal:  BMC Health Serv Res       Date:  2006-09-13       Impact factor: 2.655

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.